Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 4/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 5/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | ABL2 | P42684 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264987 | 0.85 | IL1B (0.60) | IL1BNLRP3KCNH2 | |
| SCHEMBL31269489 | 0.83 | IL1B (0.49) | IL1BNLRP3KCNH2BTK | |
| SCHEMBL31265027 | 0.83 | IL1B (0.53) | IL1BNLRP3KCNH2 | |
| SCHEMBL31265008 | 0.82 | IL1B (0.48) | IL1BNLRP3KCNH2 | |
| SCHEMBL31269470 | 0.82 | IL1B (0.48) | IL1BNLRP3KCNH2 | |
| SCHEMBL31264907 | 0.81 | IL1B (0.46) | IL1BNLRP3KCNH2HDAC4HDAC6 | |
| SCHEMBL31057095 | 0.80 | IL1B (0.45) | IL1BNLRP3KCNH2HDAC4HDAC6 | |
| SCHEMBL30973392 | 0.79 | IL1B (0.46) | IL1BNLRP3KCNH2 | |
| SCHEMBL31265017 | 0.79 | HCAR1 (0.44) | HCAR1SRCEGFRABL1ABL2 | |
| SCHEMBL31269494 | 0.78 | IL1B (0.50) | IL1BNLRP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249539-A1 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400571-A1 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400571-A1 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NOD1, NLRP3, FABP3 | IL1B 402/4885NLRP3 2/4885KCNH2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.